(917) 310-3371
Spravato (Esketamine) is a newly FDA-approved medication for the treatment of treatment-resistant depression (TRD) in adults. As a healthcare professional, it is important to understand its mechanism of action, dosing, administration, and safety profile in order to provide the best care for your patients.
Mechanism of Action
Spravato (Esketamine) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that acts on the glutamate system, which is believed to play a role in the pathophysiology of depression. Its rapid-acting antidepressant effects are thought to be due to its ability to increase synaptic plasticity and enhance neurogenesis in the prefrontal cortex.
Dosing and Administration
Spravato (Esketamine) is administered intranasally under the supervision of a healthcare provider in a certified healthcare setting. The recommended starting dose is 56 mg, which can be increased to 84 mg or decreased to 28 mg based on the patient’s response and tolerability. The medication is self-administered under the healthcare provider’s supervision, and patients are monitored for at least 2 hours after each dose.
Safety Profile
Spravato (Esketamine) has a black box warning for the risk of sedation, dissociation, and abuse and dependence. Patients should not drive or operate heavy machinery for at least 24 hours after each dose. It is contraindicated in patients with aneurysmal vascular disease, hepatic impairment, uncontrolled hypertension, or a history of psychosis or substance use disorder. Common side effects include dizziness, nausea, and vertigo.
Clinical Evidence
Clinical studies have shown that Spravato (Esketamine) is effective in reducing depressive symptoms in patients with TRD. In a randomized, double-blind, placebo-controlled trial, patients who received Spravato (Esketamine) plus an oral antidepressant had a greater reduction in depressive symptoms than those who received placebo plus an oral antidepressant. The medication’s efficacy was observed as early as 24 hours after the first dose.
Conclusion
Spravato (Esketamine) is a promising new treatment option for patients with treatment-resistant depression. As a healthcare professional, it is important to understand its mechanism of action, dosing, administration, and safety profile in order to provide the best care for your patients.
FAQs
What is Spravato (Esketamine)?
Spravato (Esketamine) is an FDA-approved medication for the treatment of treatment-resistant depression (TRD) in adults. It is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that acts on the glutamate system, which is believed to play a role in the pathophysiology of depression.
How is Spravato (Esketamine) administered?
Spravato (Esketamine) is administered intranasally under the supervision of a healthcare provider in a certified healthcare setting. The recommended starting dose is 56 mg, which can be increased to 84 mg or decreased to 28 mg based on the patient’s response and tolerability.
What are the common side effects of Spravato (Esketamine)?
Common side effects of Spravato (Esketamine) include dizziness, nausea, and vertigo. Patients may also experience sedation, dissociation, and abuse and dependence, which are serious risks associated with the medication.
Is Spravato (Esketamine) safe for all patients with depression?
No, Spravato (Esketamine) is contraindicated in patients with aneurysmal vascular disease, hepatic impairment, uncontrolled hypertension, or a history of psychosis or substance use disorder. Patients should be carefully screened before receiving the medication to ensure their safety.
What is the clinical evidence supporting the use of Spravato (Esketamine) for TRD?
Clinical studies have shown that Spravato (Esketamine) is effective in reducing depressive symptoms in patients with TRD. In a randomized, double-blind, placebo-controlled trial, patients who received Spravato (Esketamine) plus an oral antidepressant had a greater reduction in depressive symptoms than those who received placebo plus an oral antidepressant. The medication’s efficacy was observed as early as 24 hours after the first dose.
Book an Appointment
If you or a loved one is struggling with treatment-resistant depression, Nao Medical is here to help. We offer Spravato (Esketamine) treatment under the supervision of experienced healthcare providers in a safe and comfortable environment. Book an appointment today to learn more about our mental health services and how we can help you.
Note: This blog post is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.
